In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Agios Pharmaceuticals, Inc.

https://www.agios.com/

Latest From Agios Pharmaceuticals, Inc.

Servier: Precision Approach To Immunotherapy Will Define New Oncology Era

Two oncology chiefs from the French firm talked to Scrip about how its pipeline echoes the emerging intersection between precision medicine and immuno-oncology and how biology is taking precedence over technology in cancer R&D.

Cancer Strategy

Biohaven Relaunches As Biohaven Ltd. After Pfizer Buyout Closes

As signaled when Pfizer acquired Biohaven’s Nurtec and CGRP assets, Biohaven will continue under a modified name, with a focus on epilepsy, obsessive compulsive disorder and spinal muscular atrophy.

Business Strategies Companies

EMA OKs First Drug To Prevent RSV Infection In Babies

A new medicine to protect newborns and infants from RSV infection and a new treatment for DLBCL are among a dozen drugs that have been recommended for pan-EU approval.

Europe Approvals

Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.

Companies Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register